Minimizing infliximab toxicity in the treatment of inflammatory bowel disease

Digestive and Liver Disease

Volumn 40, Issue SUPPL. 2, 2008, Pages

  Orlando, A ^a   Mocciaro, F ^a   Civitavecchia, G ^a   Scimeca, D ^a   Cottone, M ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Inflammatory bowel disease; Infliximab; Safety; Toxicity

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; DIPHENHYDRAMINE; INFLIXIMAB; ISONIAZID; LAMIVUDINE; MEPREDNISONE; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PLACEBO; PREDNISONE; PYRIDOXINE; TUBERCULIN;

ABSCESS; ARTICLE; BACTERIAL INFECTION; BREAST ADENOCARCINOMA; BRONCHITIS; CANCER RISK; CELLULITIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLON CANCER; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MILK LEVEL; DRUG SAFETY; DYSPHAGIA; ENTERITIS; FEVER; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION RISK; INTESTINE OBSTRUCTION; INTESTINE STENOSIS; INTRAHEPATIC CHOLESTASIS; LEUKOCYTOSIS; LEUKOPENIA; LIVER DISEASE; LIVER FAILURE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MOTOR NEUROPATHY; MYALGIA; MYCOSIS; NEUROLOGIC DISEASE; NEUTROPENIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCYTOPENIA; PATIENT SELECTION; PHARYNGITIS; PNEUMONIA; POLYARTHRITIS; PROTOZOAL INFECTION; PRURITUS; RASH; RECTUM CARCINOMA; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCREENING TEST; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SINUSITIS; SMALL INTESTINE CANCER; SORE THROAT; SPONTANEOUS ABORTION; SWEATING; T CELL LYMPHOMA; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45849105505     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(08)60532-0     Document Type: Article

References (81)

1. Lichtenstein G., Feagan B., Cohen R., Salzberg B., Diamond R., Chen D., et al. Serious infections and mortality in association with tharapies for Crohn's disease: TREAT Registry. Clin Gastroen-terol Hepatol 4 (2006) 621-630
2. Data on file-Centocor, accessed Aug-Oct, 2006.
3. Hwang W., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
4. Hanauer S., Feagan B., Lichtenstein G., Mayer L., Schreiber S., Colombel J., et al. Maintenance Infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
5. Colombel J.-F., Loftus E., Tremaine W., Egan L., Harmsen W., Schleck C., et al. The safety profile of Infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
6. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Car-bonez A., et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
7. Farrell R., Alsahli M., Jeen Y.-T., Falchuk K., Peppercorn M., and Michetti P. Intravenous hydrocortisone premedication reduces antibodies to Infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
8. Orlando A., Colombo E., Kohn A., Biancone L., Rizzello F., Viscido A., et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37 (2005) 577-583
9. Hanauer S. Review article: safety of Infliximab in clinical trials. Aliment Pharmacol Ther 13 Suppl 4 (1999) 16-22
10. Hanauer S., Rutgeerts P., and D'Haens G. Delayed hypersensitivity to Infliximab reinfusion after a 2-4 year interval without treatment. Gastroenterology 116 (1999) A731
11. Sandborn W., and Hanauer S. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 97 (2002) 2962-2972
12. Abe T., Takeuchi T., Miyasaka N., Hashimoto H., Kondo H., Ichikawa Y., et al. A multicenter, double-blind, randomized, placebo controlled trial of Infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33 (2006) 37-44
13. Am J Gastroenterol 101 (2006) 1030-1038
14. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
15. Sandborn W., and Loftus E. Balancing the risks and benefits of Infliximab in the treatment of inflammatory bowel disease. Gut 53 (2004) 780-782
16. Lichtenstein G. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 100 (2005) 1433-1435
17. Lichtenstein G., Abreu M., Cohen R., and Tremaine W. American Gas-troenterological Association Institute technical review on corticos-teroids, immunomodulators, and Infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
18. Vermeire S., and Rutgeerts P. Antibody responses in Crohn's disease. Gastroenterology 126 (2004) 601-604
19. Reich K., Nestle F., Papp K., Ortonne J., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
20. Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125 (2003) 32-39
21. Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., and Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 1051 (2005) 559-569
22. Klapman J., Ene-Stroescu D., Becker M., and Hanauer S. A lupuslike syndrome associated with Infliximab therapy. Inflamm Bowel Dis 9 (2003) 176-178
23. Nancey S., Blanvillain E., Parmentier B., Flourie B., Bayet C., Bien-venu J., et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 11 (2005) 986-991
24. Van Assche G., Vermeire S., and Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 22 (2006) 370-376
25. Cornillie F., Shealy D., D'Haens G., Geboes K., Van Assche G., Ce-uppens J., et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15 (2001) 463-473
26. Remicade (Infliximab); prescribing information 2005.
27. Sands B., Anderson F., Bernstein C., Chey W., Feagan B., Fedorak R., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
28. Rutgeerts P., Sandborn W., Feagan B., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
29. Ljung T., Karlen P., Schmidt D., Hellstrom P., Lapidus A., Janczewska I., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
30. Bongartz T., Sutton A., Sweeting M., Buchan I., Matteson E., and Mon-tori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295 (2006) 2275-2285
31. Wallis R., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by Infliximab. Clin Infect Dis 41 Suppl 3 (2005) 194-198
32. Keane J., Gershon S., Wise R., Mirabile-Levens E., Kasznica J., Schwieterman W., et al. Tuberculosis associated with Infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
33. American Thoracic Society, CDC, and Infectious Disease Society of America. Treatment of tubercolosis. MMWR Morb Mortal Wkly Rep 52 (2003) 1-80
34. Arend S., Breedveld F., and van Dissel J. TNF-alpha blockade and tuberculosis: better look before you leap. Netherlands J Med 61 (2003) 111-119
35. Mow W., Abreu-Martin M., Papadakis K., Pitchon H., Targan S., and Vasiliauskas E. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before Infliximab therapy. Clin Gastroenterol Hepatol 2 (2004) 309-313
36. Ardizzone S., Maconi G., Colombo E., Manzionna G., Bollani S., and Bianchi Porro G. Perianal fistulae following Infliximab treatment: clinical and endosonographic outcomes. Inflamm Bowel Dis 10 (2004) 91-96
37. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with Infliximab and low dose methotrex-ate. Ann Rheum Did 62 (2003) 686-687
38. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J. Chronic hepatitis B reactivation following Infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
39. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Sub-fulminant hepatitis B after Infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
40. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., and Cottone M. Occult hepatitis B and Infliximab-induced HBV reactivation. Inflamm Bowel Dis 13 (2007) 508-509
41. Marzano A., Angelucci P., Androne P., Brunetto M., Bruno R., Burra P., et al. Focus on Prophylaxis and therapy of hepatitis B in immuno-compromised patients (2005). www.webaisf.org
42. Parke F., and Reveille J. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004) 800-804
43. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
44. Ekbom A., Helmick C., Zack M., and Adami H. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336 (1990) 357-359
45. Farrell R., Ang Y., Kileen P., O'Briain D., Kelleher D., Keeling P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 (2000) 514-519
46. Persson P., Karlen P., Bernell O., Leijonmarck C., Brostrom O., Ahlbom A., et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 107 (1994) 1675-1679
47. Lewis J., Bilker W., Brensinger C., Deren J., Vaughn D., and Strom B. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
48. Askling J., Brandt L., Lapidus A., Karlen P., Bjorkholm M., Lofberg R., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 (2005) 617-622
49. Bernstein C., Blanchard J., Kliewer E., and Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
50. Kandiel A., Fraser A., Korelitz B., Brensinger C., and Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
51. Lemann M., Mary J., Colombel J., Duclos B., Soule J., Lerebours E., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2005) 1812-1818
52. Jess T., Gamborg M., Matzen P., Munkholm P., and Sorensen T. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100 (2005) 2724-2729
53. Eaden J., Abrams K., and Mayberry J. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
54. Sandborn W., and Loftus E. Balancing the risks and benefits of Infliximab in the treatment of inflammatory bowel disease. Gut 53 (2004) 780-782
55. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S., Present D., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
56. Biancone L., Orlando A., Kohn A., Colombo E., Sostegni R., Angelucci E., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233
57. Lichtenstein G. Safety of Infliximab and other Crohn's disease therapies - Treat™ registry data with nearly 15.000 patients-years of follow-up. Gastroenterology 130 suppl 4 (2006) A71 490.
58. Mackey A., Green L., Liang L., Dinndorf P., and Avigan M. Hep-atosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroen-terol Nutr 44 (2007) 265-267
59. Biancone L., Calabrese E., Petruzziello C., and Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 78-91
60. Gupta G., Gelfand J., and Lewis J. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterol-ogy 129 (2005) 819-826
61. Khanna D., McMahon M., and Furst D. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27 (2004) 307-324
62. Khanna D., McMahon M., and Furst D. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum 50 (2004) 1040-1050
63. Dinesh K., McMaohn M., and Furst D. Anti-tumor necrosis factor alpha therapy and heart failure. Arthritis Rheum 50 (2004) 1040-1050
64. Chung E., Packer M., Lo K., Fasanmade A., and Willerson J. Randomised, double-blind, placebo controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
65. Lichtenstein G., Olson A., Travers S., Diamond R., Chen D., Pritchard M., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 101 (2006) 1030-1038
66. Maini R., St Clair E., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
67. Desai S., and Furst D. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20 (2006) 757-790
68. Mahadevan U., and Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 131 (2006) 283-311
69. Katz J., Antoni C., Keenan G., Smith D., Jacobs S., and Lichtenstein G. Outcome of pregnancy in women receiving Infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroen-terol 99 (2004) 2385-2392
70. Mahadevan U., Kane S., Sandborn W., Cohen R., Hanson K., Terdi-man J., et al. Intentional Infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21 (2005) 733-738
71. Peltier M., James D., and Ford J. Infliximab levels in breast-milk of a nursing Crohn's patient. Am J Gastroenterol 96 (2001) P258
72. Vasiliauskas E., Barry M., and Dubinsky M. High serum levels of In-fliximab detected in the newborn of a mother receiving Infliximab during pregnancy. Gastroenterology 128 (2005) P33
73. Jess T., Winther K., Munkholm P., Langholz E., and Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 122 (2002) 1808-1814
74. Loftus Jr. E., Silverstein M., Sandborn W., Tremaine W., Harm-sen W., and Zinsmeister A. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence and survival. Gastroen-terology 114 (1998) 1161-1168
75. Farmer R., Whelan G., and Fazio V. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88 (1985) 1818-1825
76. Ekbom A., Helmick C., Zack M., Holmberg L., and Adami H. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 103 (1992) 954-960
77. Ljung T., Karlen P., Schmidt D., Hellstrom P., Lapidus A., Janczewska I., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
78. Hanauer S., Sandborn W., Rutgeerts P., Fedorak R., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
79. Rutgeerts P., Sandborn W., Enns R., Hanauer S., Colombel J., Kent J., et al. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's Disease who had secondary failure to Infliximab therapy: results of the GAIN (Gauging Adalimumab efficacy in Infliximab Non-responders) study. Gut 55 Suppl (2006) A20 OP-G-86.
80. Colombel J., Sandborn W., Rutgeerts P., Enns R., Hanauer S., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
81. Sandborn W., Hanauer S., Rutgeerts P., Fedorak R., Lukas M., Macintosh D., et al. Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial. Gut 56 (2007) 1232-1239